Inbrija is a medicine used to treat adults with Parkinson’s disease (a progressive brain disease that causes shaking and muscle stiffness and slows movement). Inbrija is used to treat symptoms during ‘off’ periods (times when the patient has more difficulty moving about) that occur while the patient is taking their usual treatment of a combination of levodopa and an inhibitor of dopa\-decarboxylase. Inbrija contains the active substance levodopa.
Therapeutic Indication
Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa\-decarboxylase inhibitor.
Therapeutic Area (MeSH)
ATC Code
N04BA01
ATC Item
N/A
Pharmacotherapeutic Group
Anti-Parkinson drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| levodopa | N/A | levodopa |
EMA Name
Inbrija
Medicine Name
Inbrija
Aliases
N/ANo risk management plan link.
